1. < Home

tumor necrosis factor inhibitors

Associations of sociodemographic, clinical factors and HLA-B alleles with enthesitis and peripheral arthritis in patients with ankylosing spondylitis

Naovarat BS, Gensler L, Ward M, Hwang M, Tahanan A, Rahbar MH, Ishimori M, Lee M, Brown MA, Weisman MH, Reveille JD. Associations of sociodemographic,[...]

By sjmartinez • March 15, 2025
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad[...]

By sjmartinez • April 14, 2024
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of[...]

By sjmartinez • June 13, 2023